QIAGEN

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell QIAGEN and other ETFs, options, and stocks.

About QGEN

QIAGEN NV is a holding company, which engages in the provision of Sample to Insight solutions that enable customers to gain valuable molecular insights from samples containing the building blocks of life. Its sample technologies isolate and process DNA, RNA, and proteins from blood, tissue, and other materials. 

CEO
Thierry L. Bernard
CEOThierry L. Bernard
Employees
5,654
Employees5,654
Headquarters
Venlo, Limburg
HeadquartersVenlo, Limburg
Founded
1996
Founded1996
Employees
5,654
Employees5,654

QGEN Key Statistics

Market cap
8.44B
Market cap8.44B
Price-Earnings ratio
20.38
Price-Earnings ratio20.38
Dividend yield
0.63%
Dividend yield0.63%
Average volume
1.36M
Average volume1.36M
High today
$41.56
High today$41.56
Low today
$40.74
Low today$40.74
Open price
$41.44
Open price$41.44
Volume
1.15M
Volume1.15M
52 Week high
$57.82
52 Week high$57.82
52 Week low
$38.80
52 Week low$38.80

Stock Snapshot

The current QIAGEN(QGEN) stock price is $40.96, with a market capitalization of 8.44B. The stock trades at a price-to-earnings (P/E) ratio of 20.38 and offers a dividend yield of 63.2%.

As of 2026-04-16, QIAGEN(QGEN) stock has fluctuated between $40.74 and $41.56. The current price stands at $40.96, placing the stock +0.5% above today's low and -1.4% off the high.

The QIAGEN(QGEN)'s current trading volume is 1.15M, compared to an average daily volume of 1.36M.

During the past year, QIAGEN(QGEN) stock moved between $38.80 at its lowest and $57.82 at its peak.

During the past year, QIAGEN(QGEN) stock moved between $38.80 at its lowest and $57.82 at its peak.

QGEN News

Simply Wall St 1d
How Investors May Respond To Qiagen Entering Rapid Bloodstream Infection Testing With New Panel

In April 2026, QIAGEN N.V. expanded its QIAstat-Dx syndromic testing platform into bloodstream infections with the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AM...

How Investors May Respond To Qiagen Entering Rapid Bloodstream Infection Testing With New Panel
TipRanks 2d
Qiagen expands into bloodstream infection syndromic testing

The company states: “QIAGEN (QGEN) announced its expansion into syndromic testing for bloodstream infections with the launch of the CE-IVDR-certified QIAstat-Dx...

Simply Wall St 2d
Is Qiagen Offering Value After Mixed Share Price Performance?

Investors may be wondering whether Qiagen is offering fair value at around US$41.91, or if the current price leaves too much on the table for comfort. The shar...

Is Qiagen Offering Value After Mixed Share Price Performance?

Analyst ratings

65%

of 23 ratings
Buy
34.8%
Hold
65.2%
Sell
0%

More QGEN News

TipRanks 2d
Qiagen price target raised to EUR 44 from EUR 43 at Morgan Stanley

Morgan Stanley analyst Aisyah Noor raised the firm’s price target on Qiagen (QGEN) to EUR 44 from EUR 43 and keeps an Equal Weight rating on the shares. Unlock...

People also own

Based on the portfolios of people who own QGEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.